Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2021-07-01
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma
NCT02732652
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
NCT03471897
Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma
NCT02732665
Biomarkers of Renal Cancer
NCT05785052
Urine Proteome of Surgical Patients and Healthy Volunteers
NCT01538823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal Call Carcinoma
Patrients with renal cancer
GaGnostic
Plasma
GaGnostic
Serum
GaGnostic
Urine
Oncocytoma
Patients with oncocytoma
GaGnostic
Plasma
GaGnostic
Serum
GaGnostic
Urine
Healthy persons
Patients with CT scan shows no renal cancer
GaGnostic
Plasma
GaGnostic
Serum
GaGnostic
Urine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GaGnostic
Plasma
GaGnostic
Serum
GaGnostic
Urine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
3. Sign up information consent
4. Can perform protocol procedure
Exclusion Criteria
2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Elypta
INDUSTRY
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nessn Azawi
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zealand University Hospital
Roskilde, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJ-894
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.